The combination of docetaxel with carboplatin, trastuzumab, and pertuzumab (TCHP) is one of the most frequently used neoadjuvant regimens for patients with HER2+ breast cancer who are candidates for neoadjuvant chemotherapy.[9] Patients undergoing neoadjuvant chemotherapy with TCHP are administered prophylactic growth factor support with pegfilgrastim to mitigate the risk of febrile neutropenia. Here, ERBB2 is linked to breast carcinoma.